May 7, 2020: Epidemiological factors among transgender women; revised PrEP indication estimates for MSM; trends in HIV strain similarity between younger and older MSM; current hepatitis C epidemic among British MSM with HIV.
VOCAL-NY has kept its doors open through the COVID-19 pandemic to serve people who use drugs and may be living with hepatitis C, but how it provides services has changed.
Retire? No, Thanks! This Doc Instead Moved to West Virginia to Fight HIV, Hepatitis C, and the Opioid Crisis
In a poor and conservative state, Judith Feinberg, M.D., aims to expand harm reduction—and bring treatment to active drug users.
Addiction needs to be addressed by prevention and treatment, but policy makers need skin in the game too.
As With HIV, New York State Was Set to Lead the Nation to End Hepatitis C. But Why Haven’t the Recommendations Been Made Public?
Activist and member of the state task force Annette Gaudino would like the public to know.
IPERGAY scientists recommended that clinicians screen patients who request PrEP, as well as patients who are already using it, for a number of key HCV risk factors.
Jan. 16, 2020: Texting (and stigma support) vs. email for care retention; beyond-childhood health risks for HIV-exposed infants; HIV, cardiovascular risk, and cognitive impairment; direct-acting antiviral efficacy and prescription delays.
Jan. 9, 2020: Bone loss after HIV treatment initiation; aging and antiretroviral dosage; more U=U evidence for women; viral suppression and executive function.
The HIV services organization Housing Works implemented a hepatitis C treatment program in New York City, with very high completion rates.
Montreal scientists found that 88% of cannabis users had an undetectable viral load. This suggests that a very large majority of cannabis users did not have problems adhering to antiretroviral therapy.